Delivery Order SPE2DR25D2014-SPE2DR26FZ96E
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,868.18 to supply CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract. The order was competitively awarded without set-aside designation and is scheduled for completion by December 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, fulfilled this order from its corporate office location, leveraging its established role as a critical pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of CAPLYTA 42 mg capsules (30-count packages) with a contract value of $7,397.74. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 9, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's demonstrated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 10.5 mg capsules (30-count units) with a ceiling value of $1,965.79. This competitively awarded, firm fixed-price delivery order was issued on December 12, 2025, with an ultimate completion date of December 15, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This contract represents a child award under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $7,064.84 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 21 mg capsules (30-count units) under a firm fixed price contract. The award was made on November 25, 2025, with an ultimate completion date of November 26, 2025, and represents a non-competitive set-aside transaction. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from its...
- The Defense Logistics Agency awarded a delivery order valued at $16,800.83 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract. The award, issued on November 14, 2025, with an ultimate completion date of November 17, 2025, represents a non-set-aside competitive award. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $13,827.40 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of CAPLYTA 42 MG capsules (30-count units). The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award to this established pharmaceutical distributor. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania location, with completion scheduled for September 9, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-unit packages) with a ceiling value of $2,971.27 under firm fixed pricing. The award, issued on November 7, 2025, with an ultimate completion date of November 10, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,299.95 to AmerisourceBergen Drug Corp for CAPLYTA 10.5 mg capsules (30-count units) on December 9, 2025, with an ultimate completion date of December 10, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a $1,222.47 delivery order to AmerisourceBergen Drug Corp on November 26, 2025, for the supply of Caplyta 21 mg capsules (30-count package), with completion expected by November 28, 2025. This firm fixed price, competitively awarded contract (no set-aside designation) will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's substantial Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,236.39 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. CAPLYTA is a pharmaceutical treatment for psychiatric conditions, reflecting the company's...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ96EDelivery Order
The Defense Logistics Agency awarded a $7,979.16 delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-unit supply) on December 12, 2025, with an ultimate completion date of December 15, 2025. This firm fixed price contract, which carries no set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle provides comprehensive global pharmaceutical support, enabling the company to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates extensive experience fulfilling variable federal medical supply requirements, with awards spanning from small-value transactions to substantial orders, positioning it as a key participant in DLA's pharmaceutical procurement operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.0k | 12/11/25 |